What is Noble Financial’s Forecast for GYRE FY2024 Earnings?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) – Noble Financial issued their FY2024 earnings estimates for Gyre Therapeutics in a report issued on Tuesday, March 11th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings per share of $0.17 for the year. Noble Financial currently has a “Outperform” rating on the stock. Noble Financial also issued estimates for Gyre Therapeutics’ Q4 2024 earnings at $0.04 EPS, Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.17 EPS, FY2027 earnings at $1.72 EPS and FY2028 earnings at $2.90 EPS.

Gyre Therapeutics Price Performance

GYRE opened at $12.11 on Thursday. The company’s 50-day moving average is $11.27 and its 200 day moving average is $12.31. Gyre Therapeutics has a fifty-two week low of $8.26 and a fifty-two week high of $19.96.

Institutional Trading of Gyre Therapeutics

Large investors have recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. purchased a new stake in Gyre Therapeutics during the fourth quarter worth about $1,225,000. FMR LLC purchased a new position in shares of Gyre Therapeutics in the third quarter worth about $47,000. Charles Schwab Investment Management Inc. increased its stake in shares of Gyre Therapeutics by 392.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after purchasing an additional 90,557 shares in the last quarter. State Street Corp increased its stake in shares of Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares in the last quarter. Finally, Barclays PLC increased its stake in shares of Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Insider Buying and Selling

In related news, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00. Following the completion of the sale, the president now owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 36,054 shares of company stock worth $406,537. Insiders own 19.52% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.